Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICTAM: MIPD for Tamoxifen in Breast Cancer
NCT05525481Phase 4Unknown
- Sponsor
- Erasmus MC
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tamoxifen in breast cancer, sponsored by Erasmus MC. Status: unknown.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05525481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525481.